Scienture Holdings (SCNX)
NASDAQ:SCNX
Want to see SCNX full AI Analyst Report?
Top Page
Scienture Holdings
(NASDAQ:SCNX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.39
▼(-28.91% Downside)
Action:Reiterated
Date:05/16/26
The score is driven primarily by very weak profitability and ongoing cash burn, which outweigh the benefit of low recent leverage. Technicals are neutral and do not signal strong upside momentum, while negative earnings (negative P/E) limit valuation support. The recent structured financing adds liquidity but introduces tighter covenants and potential downside risk.
Positive Factors
Low Leverage / Balance Sheet Health
Very low reported leverage reduces near-term refinancing and solvency risk, giving management more time to execute commercialization. A light debt load preserves optionality for R&D and partnering and lowers immediate liquidity pressure versus highly levered peers.
Negative Factors
Ongoing Cash Burn
Sustained negative operating and free cash flows show the business consumes cash to operate and commercialize. This creates structural dependency on external financing, risks dilution or onerous funding terms, and constrains the firm's ability to invest without new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Health
Very low reported leverage reduces near-term refinancing and solvency risk, giving management more time to execute commercialization. A light debt load preserves optionality for R&D and partnering and lowers immediate liquidity pressure versus highly levered peers.
Read all positive factors
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.78M
Dividend YieldN/A
Average Volume (3M)4.08M
Price to Earnings (P/E)―
Beta (1Y)3.37
Revenue Growth-73.18%
EPS Growth92.38%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-210.15
Enterprise Value/Revenue-7.38K
Enterprise Value/Gross Profit42.31K
Enterprise Value/Ebitda89.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scienture Holdings Business Overview & Revenue Model
Company Description
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, h...
How the Company Makes Money
null...
Scienture Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 477.68K | 431.61K | 136.64K | 1.36M | 10.25M | 9.89M |
| Gross Profit | -83.35K | 331.48K | 6.00K | 49.03K | 5.52M | 4.75M |
| EBITDA | -39.60M | -38.93M | -17.39M | -6.29M | -1.87M | -5.15M |
| Net Income | -41.85M | -41.51M | 9.07M | -17.84M | -3.47M | -5.32M |
Balance Sheet | ||||||
| Total Assets | 80.66B | 84.18B | 104.85M | 12.53M | 3.71M | 5.77M |
| Cash, Cash Equivalents and Short-Term Investments | 3.54B | 6.66B | 308.10K | 314.00 | 1.09M | 3.12M |
| Total Debt | 10.00M | 24.14M | 3.53M | 6.76M | 1.58M | 1.25M |
| Total Liabilities | 13.84B | 14.06B | 25.78M | 11.99M | 3.37M | 2.00M |
| Stockholders Equity | 66.82B | 70.12B | 79.07M | 542.35K | 763.14K | 3.77M |
Cash Flow | ||||||
| Free Cash Flow | -2.93B | -13.38B | -14.28M | -2.23M | -1.56M | -2.59M |
| Operating Cash Flow | -2.93B | -13.38B | -14.27M | -2.23M | -1.56M | -2.57M |
| Investing Cash Flow | 0.00 | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K |
| Financing Cash Flow | -184.96M | 19.73B | -12.98M | 1.41M | -35.17K | -208.18K |
Scienture Holdings Technical Analysis
Positive
0.55
Price Trends
0.39
Positive
0.42
Negative
0.61
Negative
Market Momentum
<0.01
Negative
54.43
Neutral
52.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Positive. The current price of 0.55 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.39, and below the 200-day MA of 0.61, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 52.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCNX.
Scienture Holdings Risk Analysis
Scienture Holdings disclosed 45 risk factors in its most recent earnings report. Scienture Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scienture Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $16.78M | -4.01 | -44.11% | ― | -73.18% | 92.38% | |
| ― | $643.74K | -0.09 | -8.26% | ― | -28.30% | -86.73% | |
43 Neutral | $9.21M | -0.68 | 336.68% | ― | 18.05% | 86.68% | |
41 Neutral | $5.23M | ― | -112.81% | ― | 77.50% | 99.28% |
* Healthcare Sector Average
SCNX
Scienture Holdings
0.41
-0.47
-53.07%
ZCMD
Zhongchao
0.17
-9.35
-98.25%
HCTI
Healthcare Triangle
2.58
-445.62
-99.42%
VSEE
VSee Health
0.19
-0.93
-83.13%
MGRX
Mangoceuticals, Inc.
0.43
-1.70
-79.81%
Scienture Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Scienture Holdings Issues Updated Investor Presentation Disclosure
Neutral
May 5, 2026
On May 5, 2026, Scienture Holdings, Inc. posted a revised investor presentation on its website to support upcoming meetings with analysts, potential investors and other interested parties. The presentation is described as summary information that ...
Business Operations and StrategyPrivate Placements and Financing
Scienture Holdings Secures $11.4 Million Structured Financing Deal
Negative
May 1, 2026
On April 27, 2026, Scienture Holdings, Inc. entered into and closed a financing deal with Streeterville Capital, LLC, issuing two secured promissory notes totaling $11.42 million, with $8 million delivered at closing and $3 million placed in a con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.